Valeant investor Doyle departs Pershing Square to focus on Novocure
NovoCure (NSDQ:NVCR) said earlier this month it inked a deal to formally establish William Doyle as its new executive chairman. Doyle previously served as chairman and director for the company.
“Given our dynamic growth, we believe there is significant value in expanding Bill’s role as an executive officer at Novocure as we work together to establish Tumor Treating Fields, or TTFields, as a new treatment modality for a variety of solid tumors. Since his initial involvement in 2003, Bill’s leadership has been instrumental in setting the company’s strategic direction as we’ve worked together to build the immediate commercial opportunity for TTFields in glioblastoma and to develop TTFields as a potential treatment for other solid tumors,” CEO Asaf Danziger said in a press release.
